Back to Search
Start Over
Suberanilohydroxamic Acid as a Pharmacological Kruppel‐Like Factor 2 Activator That Represses Vascular Inflammation and Atherosclerosis
- Source :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Publication Year :
- 2017
- Publisher :
- John Wiley and Sons Inc., 2017.
-
Abstract
- Background Kruppel‐like factor 2 ( KLF 2) is an important zinc‐finger transcription factor that maintains endothelial homeostasis by its anti‐inflammatory, ‐thrombotic, ‐oxidative, and ‐proliferative effects in endothelial cells. In light of the potent vasoprotective effects of KLF 2, modulating KLF 2 expression or function could give rise to new therapeutic strategies to treat cardiovascular diseases. Methods and Results High‐throughput drug screening based on KLF 2 promoter luciferase reporter assay was performed to screen KLF 2 activators. Real‐time PCR and western blot were used to detect gene and protein expression. Identified KLF 2 activator was orally administered to ApoE −/− mice to evaluate anti‐atherosclerotic efficacy. By screening 2400 compounds in the Spectrum library, we identified suberanilohydroxamic (SAHA) acid, also known as vorinostat as a pharmacological KLF 2 activator through myocyte enhancer factor 2. We found that SAHA exhibited anti‐inflammatory effects and attenuated monocyte adhesion to endothelial cells inflamed with tumor necrosis factor alpha. We further showed that the inhibitory effect of SAHA on endothelial inflammation and ensuing monocyte adhesion was KLF 2 dependent using KLF 2‐deficient mouse lung endothelial cells or KLF 2 small interfering RNA– depleted human endothelial cells. Importantly, we observed that oral administration of SAHA reduced diet‐induced atherosclerotic lesion development in ApoE −/− mice without significant effect on serum lipid levels. Conclusions These results demonstrate that SAHA has KLF 2‐dependent anti‐inflammatory effects in endothelial cells and provide the proof of concept that KLF 2 activation could be a promising therapeutic strategy for treating atherosclerosis.
- Subjects :
- 0301 basic medicine
Male
Vasculitis
Mice, Knockout, ApoE
THP-1 Cells
Anti-Inflammatory Agents
Kruppel-Like Transcription Factors
Administration, Oral
Inflammation
Oxidative phosphorylation
Hydroxamic Acids
Transfection
Vascular Medicine
Monocytes
03 medical and health sciences
Krüppel
Chlorocebus aethiops
medicine
Cell Adhesion
Animals
Humans
Promoter Regions, Genetic
Transcription factor
Original Research
Vorinostat
Activator (genetics)
business.industry
SAHA
Endothelial Cells
Atherosclerosis
Coculture Techniques
3. Good health
High-Throughput Screening Assays
Endothelial stem cell
Disease Models, Animal
030104 developmental biology
inflammation
KLF2
COS Cells
Cancer research
endothelial cell
RNA Interference
medicine.symptom
Cardiology and Cardiovascular Medicine
business
Homeostasis
Signal Transduction
Subjects
Details
- Language :
- English
- ISSN :
- 20479980
- Volume :
- 6
- Issue :
- 12
- Database :
- OpenAIRE
- Journal :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Accession number :
- edsair.doi.dedup.....03bd7d770455af66157ef9d4f72c1aac